Murphy, Robin J.
Godfrey, Kate
Shaw, Alexander D.
Muthukumaraswamy, Suresh
Sumner, Rachael L.
Funding for this research was provided by:
Health Research Council of New Zealand (20/845)
Article History
Received: 13 October 2023
Accepted: 10 January 2024
First Online: 5 February 2024
Declarations
:
: Ethics approval was awarded by the University of Auckland Health and Disability Ethics Committee (19/STH/91) and the HRC Standing Committee on Therapeutic Trials (Online reference: 19/SCOTT/108; HRC reference: 2227; Department of Health reference: TT55-0016 (2455)) in accordance with the National Ethical Standards for Health and Disability Research. Trial registered with Australian New Zealand Clinical Trials Registry: A randomised, double blind, placebo-controlled trial of repeated microdoses of lysergic acid diethylamide (LSD) in healthy volunteers; ExternalRef removed; ACTRN12621000436875. Informed consent has been obtained from all the participants. A copy of the participant information sheet and informed consent form are available in the supplementary documentation of the trial protocol [CitationRef removed]. This paper adheres to the CONSORT guidelines.
: Not applicable.
: SM, and RLS have received research funding from MindBio Therapeutics Ltd. to conduct further work in psychedelic microdosing. SM has received funding from atai Life Sciences for unrelated research work. No other authors report biomedical financial interests or conflicts of interest.